相关实验视频
Updated: Sep 17, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.5K
对GSK3β酸化介导的tau聚合的药理干预,通过调节富含proline的tau域的相分离来调节tau聚合
Shan Sun1, Siqian Chen1, Junqiu He2
1Faculty of Health Sciences, University of Macau, Taipa, Macau, China; Jiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
概括
异常的蛋白凝结,阿尔茨海默氏症的标志,是由proline丰富域 (PRD) 酸化驱动的. 抑制糖原合成酶激酶3β (GSK3β) 降低了陶凝结,并减缓了疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 细胞生物学 细胞生物学
背景情况:
- 陶聚合成神经纤维状结是神经退行性疾病的核心,如阿尔茨海默氏症.
- 蛋白异常相位分离导致病态聚合物形成.
- 凝固的精确分子机制和治疗策略仍然不清楚.
研究的目的:
- 为了研究凝的分子机制.
- 探索不同域在凝结中的作用.
- 评估药理学上向凝的潜力.
主要方法:
- 利用光遗传学 (光滴) 在细胞模型中研究凝结.
- 采用细胞生物学技术来分析tau行为.
- 应用药理干预来调节凝结.
主要成果:
- 陶蛋白丰富域 (PRD) 的酸化,由糖原合成酶激酶3β (GSK3β) 调节,对于陶凝结至关重要.
- 陶PRD酸化會影響它對核斑點的錯誤定位.
- 药理上抑制GSK3β有效地减少了异常的凝结.
结论:
- 陶氏PRD的GSK3β介导酸化是病理性陶氏凝聚的关键驱动因素.
- 向GSK3β可以阻碍陶氏凝结,并减缓陶氏病变中的疾病进展.
- 基于凝结的治疗策略显示出治疗神经退行性疾病的前景.
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Phosphorylation
51.2K
The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
51.2K
Protein Kinases and Phosphatases
13.5K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.5K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K

